ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,575.90
-1.39%
S&P ASX All Technology
2,970.40
-1.25%
Brent Oil
88.165
0.00%
US Dollar vs AUD
1.53139
0.00%
Bitcoin
63,409.48
-0.52%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Acer Therapeutics Inc (ACER)

  7. Acer Therapeutics Inc (ACER) News

ACER

Acer Therapeutics (ACER)

Acer Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACER
DateTimeSourceHeadlineSymbolCompany
09/11/202308:13Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ACERAcer Therapeutics Inc
09/11/202308:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
02/11/202323:51Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACERAcer Therapeutics Inc
02/11/202323:50Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ACERAcer Therapeutics Inc
02/11/202323:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
02/11/202323:30GlobeNewswire Inc.Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related ProposalsNASDAQ:ACERAcer Therapeutics Inc
30/10/202322:24Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACERAcer Therapeutics Inc
11/10/202308:17Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:ACERAcer Therapeutics Inc
31/08/202323:29Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ACERAcer Therapeutics Inc
31/08/202323:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
31/08/202321:30GlobeNewswire Inc.Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial ProductNASDAQ:ACERAcer Therapeutics Inc
31/08/202306:05GlobeNewswire Inc.Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical EuropeNASDAQ:ACERAcer Therapeutics Inc
15/08/202306:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACERAcer Therapeutics Inc
15/08/202306:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
15/08/202306:05GlobeNewswire Inc.Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
26/06/202323:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
26/06/202322:30GlobeNewswire Inc.Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and FounderNASDAQ:ACERAcer Therapeutics Inc
08/06/202306:03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
23/05/202306:17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
16/05/202307:29Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ACERAcer Therapeutics Inc
16/05/202307:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
16/05/202307:10GlobeNewswire Inc.Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
04/05/202320:00Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
01/05/202323:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
01/05/202322:30GlobeNewswire Inc.Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of ScheduleNASDAQ:ACERAcer Therapeutics Inc
27/04/202320:25Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)NASDAQ:ACERAcer Therapeutics Inc
15/04/202306:29Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ACERAcer Therapeutics Inc
28/03/202307:18Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ACERAcer Therapeutics Inc
28/03/202307:13Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ACERAcer Therapeutics Inc
28/03/202307:01GlobeNewswire Inc.Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACER

Your Recent History

ASX
RIO
Rio Tinto
NYSE
DIS
Walt Disney
CCOM
SILVER
SILVER
FX
AUDCAD
AUD vs CAD
ASX
XTO
S&P ASX 100
ASX
ORG
Origin Energy
ASX
WES
Wesfarmers
FX
GBPAUD
Sterling vs AUD
NYSE
XOM
Exxon Mobil
NASDAQ
NVDA
NVIDIA
NYSE
MRK
Merck
ASX
SUN
Suncorp
ASX
FMG
Fortescue
ASX
WOW
Woolworths
NYSE
JPM
JP Morgan Chase
ASX
WBC
Westpac Banking
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved